Showing results (61-70 of 72) with videos related to
Sort By:
Pageof 8
Cell Death and Differentiation|May 21, 2013
Disease-relevant proteostasis regulation of cystic fibrosis transmembrane conductance regulatorV R Villella, S Esposito, E M Bruscia, et al.Journal of Lower Genital Tract Disease|April 4, 2020
Challenges Associated With Cervical Cancer Screening and Management in Obese Women: A Provider PerspectiveMegan A Clarke, L Stewart Massad, Michelle J Khan, et al.Journal of Lower Genital Tract Disease|December 20, 2023
2019 ASCCP Risk-Based Management Consensus Guidelines: Updates Through 2023Rebecca B Perkins, Richard S Guido, Philip E Castle, et al.Journal of Lower Genital Tract Disease|April 4, 2020
A Study of Partial Human Papillomavirus Genotyping in Support of the 2019 ASCCP Risk-Based Management Consensus GuidelinesMaria Demarco, Didem Egemen, Tina R Raine-Bennett, et al.Journal of Lower Genital Tract Disease|September 28, 2017
ASCCP Colposcopy Standards: How Do We Perform Colposcopy? Implications for Establishing StandardsAlan G Waxman, Christine Conageski, Michelle I Silver, et al.Journal of Lower Genital Tract Disease|September 28, 2017
ASCCP Colposcopy Standards: Role of Colposcopy, Benefits, Potential Harms, and Terminology for Colposcopic PracticeMichelle J Khan, Claudia L Werner, Teresa M Darragh, et al.Journal of Lower Genital Tract Disease|April 4, 2020
Risk Estimates Supporting the 2019 ASCCP Risk-Based Management Consensus GuidelinesDidem Egemen, Li C Cheung, Xiaojian Chen, et al.Journal of the Neurological Sciences|January 13, 2026
The impact of adding optical coherence tomography in MS diagnostic criteria on the classification of tumefactive demyelinationFiorella S Guido, John J Chen, Paul A Decker, et al.Cell Death and Differentiation|July 23, 2016
A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTRA Tosco, F De Gregorio, S Esposito, et al.Cell Death and Differentiation|April 2, 2016
A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTRA Tosco, F De Gregorio, S Esposito, et al.Pageof 8